Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 43: Daunorubicin Dose and Gemtuzumab Ozogamicin in Older AML/MDS Patients
NCT00121303Phase 3Completed
- Sponsor
- HOVON
- Start
- Jan 2005
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by HOVON. Started Jan 2005; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00121303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121303.